Current and Emerging Trends in Breast Cancer: HER2+ and HER2-Low

This publication provides a summary of key stakeholder insights on the role of antibody-drug conjugates in targeting HER2+ or HER2-low breast cancer and examines clinical trial data on treatment options for HER2+ breast cancer with brain metastases.

EP: 1.Dr. Iyengar on Trastuzumab Deruxtecan in HER2-Low Breast Cancer

EP: 2.Dr. Abdou on the Significance of the DESTINY-Breast03 Trial in HER2-Positive Breast Cancer

Now Viewing

EP: 3.Current and Emerging Trends in Breast Cancer: HER2+ and HER2-Low

Related Videos

Related Content

Advertisement

July 11th 2024

Best Practices in Treating Early-Stage NSCLC

April 11th 2024

An Evolving Treatment Paradigm: ADCs in Non–Small Cell Lung Cancer

April 21st 2023

Expanding Horizons: Antibody-Drug Conjugates in Non–Small Cell Lung Cancer

April 21st 2023

Clinical Decision Making in Advanced NSCLC without Actionable Mutations

March 10th 2023

BTK Inhibitors in MCL and CLL

January 25th 2023

Where Do ADCs Fit Into the Treatment Paradigm for Patients With NSCLC?

Related Content

Advertisement

July 11th 2024

Best Practices in Treating Early-Stage NSCLC

April 11th 2024

An Evolving Treatment Paradigm: ADCs in Non–Small Cell Lung Cancer

April 21st 2023

Expanding Horizons: Antibody-Drug Conjugates in Non–Small Cell Lung Cancer

April 21st 2023

Clinical Decision Making in Advanced NSCLC without Actionable Mutations

March 10th 2023

BTK Inhibitors in MCL and CLL

January 25th 2023

Where Do ADCs Fit Into the Treatment Paradigm for Patients With NSCLC?